Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

Theranexus announces the inclusion of the first patient in its phase 2 clinical trial evaluating its drug candidate THN102 in excessive daytime sleepiness (EDS) in patients with Parkinson's disease

Download the PDF file (397 Ko)

Theranexus presents new data on the stimulating effect of its drug candidate THN 102

Download PDF file (306 Ko)

Half-year information on the liquidity contract (in French)

Download PDF file (197 Ko)

Theranexus announces German Authorities approval for its phase 2 clinical trial in Parkinson's disease

Download the PDF (375 Ko)

Theranexus announces the publication of a scientific article on the mechanism of action of drug candidate THN102 in the international journal of neuropsychopharmacology
Download PDF file (262 Ko)

Theranexus publishes its cash position as at 31st March 2018
Download PDF file (204 Ko)

Theranexus presentation at the International Connexins Symposium (Vancouver 14-15 May 2018)
Download PDF file (273 Ko)

Oral presentation of Theranexus at the 9th European congress on narcolepsy 5 and 6 may in Montpellier
Download PDF File (279 Ko)

Publication of 2017 reference document (in French)
Download PDF file (153 Ko)

Theranexus announces its 2017 annual results and presents an update on the progress of its clinical trials
Download PDF File (427 Ko)